FLDM - Fluidigm Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.60
+0.06 (+1.08%)
At close: 4:00PM EDT

5.47 -0.13 (-2.26%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close5.54
Open5.55
Bid5.60 x 2200
Ask5.61 x 2200
Day's Range5.39 - 5.61
52 Week Range5.06 - 14.90
Volume1,566,688
Avg. Volume967,157
Market Cap388.66M
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Fluidigm Files Patent Infringement Suit Against IONpath

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court for the Northern District of California seeking to stop the infringement of its patented technology by IONpath. In the complaint, Fluidigm alleges that IONpath’s MIBI Technology infringes Fluidigm’s U.S. Patent Nos. The lawsuit seeks damages and injunctive relief requiring IONpath to stop selling its infringing MIBI Technology.

  • GlobeNewswire

    Fluidigm Revolutionizes Next-Generation Sequencing RNA Library Preparation with Microfluidic Automation

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the launch of a breakthrough RNA sequencing library preparation workflow that provides substantial cost savings and operational efficiencies for mid-to-high-throughput laboratories. Developed for use with the Fluidigm® Juno™ microfluidic system, the Advanta™ RNA-Seq NGS Library Prep Kit provides an integrated solution that enables researchers to reduce their costs for full-length stranded libraries by up to 50%.

  • GlobeNewswire

    Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)

    Fluidigm Corporation (FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of three new Imaging Mass Cytometry™ Maxpar® Human Immuno-Oncology Panel Kits and an advanced CyTOF® Software solution at the World Molecular Imaging Congress (WMIC), in Montreal, Canada. “Imaging Mass Cytometry (IMC™) is leading the way in transforming the future of highly multiplexed imaging by empowering researchers across the globe to gain an unprecedented view into the tissue microenvironment,” said Chris Linthwaite, Chief Executive Officer of Fluidigm.

  • GlobeNewswire

    Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has entered into a collaboration with the Icahn School of Medicine at Mount Sinai to develop epigenetic signatures that could identify exposure to weapons of mass destruction. Funded by an award of up to $27.8 million from the Epigenetic CHaracterization and Observation (ECHO) program of the U.S. Defense Department’s Defense Advanced Research Projects Agency (DARPA), Fluidigm will receive up to $3.9 million over four years to develop a single-cell measurement device to identify epigenetic changes in human blood using microfluidics technologies.

  • Have Insiders Been Buying Fluidigm Corporation (NASDAQ:FLDM) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Fluidigm Corporation (NASDAQ:FLDM) Shares This Year?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswire

    Fluidigm to Participate in Upcoming Health Care Investor Conferences

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences. Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Monday, September 9, 2019, at 2:15 pm ET at the Morgan Stanley 17th Annual Global Healthcare Conference in New York.

  • Thomson Reuters StreetEvents

    Edited Transcript of FLDM earnings conference call or presentation 1-Aug-19 9:00pm GMT

    Q2 2019 Fluidigm Corp Earnings Call

  • Fluidigm is Running in Place, but Expects to Break Out in 2020
    Motley Fool

    Fluidigm is Running in Place, but Expects to Break Out in 2020

    Weakness in the legacy microfluidics business is offsetting the company's best growth opportunity. What needs to happen for that to change?

  • Here's Why Fluidigm Is Getting Crushed Today
    Motley Fool

    Here's Why Fluidigm Is Getting Crushed Today

    The company reported second-quarter revenue at the low end of its expectations and well below the average Wall Street estimate.

  • Fluidigm (FLDM) Q2 2019 Earnings Call Transcript
    Motley Fool

    Fluidigm (FLDM) Q2 2019 Earnings Call Transcript

    FLDM earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results

    Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal.

  • GlobeNewswire

    Fluidigm Announces Second Quarter 2019 Financial Results

    Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal.

  • GlobeNewswire

    Jonathan Day Named VP, Commercial Operations, Americas

    Fluidigm Corporation (FLDM) today announced the appointment of Jonathan Day as Vice President, Commercial Operations, Americas. Day will be responsible for leading all commercial activities in the Americas, furthering market adoption of Fluidigm products, particularly in the growing scientific community studying the human immune system.

  • GlobeNewswire

    Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced it will introduce an automated RNA sequencing (RNA-seq) library preparation workflow in the third quarter. Developed for use with the Fluidigm® Juno™ microfluidic system, the automated RNA-seq workflow significantly reduces cost per sample and hands-on time by up to 50 percent for the molecular laboratory.

  • GlobeNewswire

    Fluidigm Announces 3rd Annual Imaging Mass Cytometry User Group Meeting

    SOUTH SAN FRANCISCO, Calif., July 30, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Fluidigm (FLDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Bill W. Colston Named to Fluidigm Board of Directors

    Fluidigm Corporation (FLDM) today announced the appointment of Bill W. Colston to the company’s Board of Directors. Colston is President of iCarbonX and has more than 30 years of experience across a range of innovative life science and technology ventures. Colston has served as President of personal health company iCarbonX since March 2019.

  • Update: Fluidigm (NASDAQ:FLDM) Stock Gained 90% In The Last Year
    Simply Wall St.

    Update: Fluidigm (NASDAQ:FLDM) Stock Gained 90% In The Last Year

    While Fluidigm Corporation (NASDAQ:FLDM) shareholders are probably generally happy, the stock hasn't had particularly...

  • GlobeNewswire

    Fluidigm Announces Conference Call and Webcast of Second Quarter 2019 Financial Results

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report second quarter 2019 financial results on Thursday, August 1, 2019, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on August 1, 2019, to discuss second quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

  • GlobeNewswire

    Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019

    SOUTH SAN FRANCISCO, Calif., June 20, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • GlobeNewswire

    Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce three new Imaging Mass Cytometry™ Maxpar® panel kits and an advanced CyTOF® software solution in the third quarter to power immuno-oncology research. Imaging Mass Cytometry is rapidly advancing our understanding of health and disease by empowering researchers around the globe to deeply profile cellular phenotypes in tumors and tissues. The new ready-to-go Maxpar panel kits for immuno-oncology studies can enable researchers to rapidly profile immune infiltrates across a range of human cancer types and treatment modalities with Imaging Mass Cytometry.

  • GlobeNewswire

    Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce seven new cadmium metal labeling kits for mass cytometry in Q3. Representing the first of a series of new metal isotopes in development, these new isotopes will empower researchers to easily design and customize larger panels to advance biomarker discovery and therapeutic development. Mass cytometry is an industry-leading tool for deep interrogation of cellular phenotypes and function in health and disease.

  • GlobeNewswire

    Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer

    Quong will lead the company’s strategy for the generation of bold scientific insights in immunology, immuno-oncology and other frontiers of human health based on Fluidigm® technology. Quong was most recently Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute.

  • GlobeNewswire

    Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 31, 2019, under Fluidigm’s 2017 Inducement Award Plan (“Plan”), as a material inducement to employment to an individual hired by Fluidigm in May 2019. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

  • GlobeNewswire

    Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today introduced the Advanta™ RNA Fusions NGS Library Prep Assay for detection of over 380 gene fusion pairs from solid tumors and hematological cancers. Developed to fuel new advances in translational and clinical cancer research, the assay uniquely empowers researchers to interrogate gene fusions from a wide range of cancer types using a simple and highly efficient automated NGS library prep workflow.